Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Slides:

Advertisements

Similar presentations

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative.

Advertisements

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab Laura.

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation Claudio G. Brunstein, Effie W. Petersdorf,

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial Lauri M. Burroughs, Eneida.

Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte.

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas Kristin Baird, Terry J. Fry,

Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation Cara L. McDermott, Brenda M. Sandmaier, Barry.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative.

Statistical Considerations in Studies of Late Effects in HCT

Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Double-Unit Cord Blood Transplantation after Myeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Phase II Study in Japan

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter.

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders Lauri M. Burroughs, Akiko.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially.

Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning

Frédéric Baron, Effie W. Petersdorf, Ted Gooley, Brenda M

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial Hirohisa Nakamae, Barry E. Storer, Rainer Storb, Jan Storek, Thomas R. Chauncey, Michael A. Pulsipher, Finn B. Petersen, James C. Wade, Michael B. Maris, Benedetto Bruno, Jens Panse, Effie Petersdorf, Ann Woolfrey, David G. Maloney, Brenda M. Sandmaier Biology of Blood and Marrow Transplantation Volume 16, Issue 3, Pages 384-394 (March 2010) DOI: 10.1016/j.bbmt.2009.11.004 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidences of grade II, III, and IV aGVHD (A) and clinical, extensive cGVHD (B). Biology of Blood and Marrow Transplantation 2010 16, 384-394DOI: (10.1016/j.bbmt.2009.11.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier product estimates of NRM and relapse (A), overall survival and progression-free survival (B), and overall survival as stratified by HCT-CI score (C). Biology of Blood and Marrow Transplantation 2010 16, 384-394DOI: (10.1016/j.bbmt.2009.11.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Recovery of lymphocyte subsets. Recovery of NK, B cells, dendritic cell precursors, CD4+ and CD8+ T cells after transplantation (A). Recovery of naive, memory/effector, CD28+ or CD28−, CD4+ and CD8+ T cells after transplantation (B). The y-axis shows the number of cells per microliter of blood. Patient medians (diamonds) and 25th-75th percentiles (error bars) are displayed. Normal medians (of 104 normal adults) are indicated by the dashed horizontal lines; the thick horizontal lines denote the normal 10th-90th percentiles. Pretransplantation studies are arbitrarily shown as performed using blood collected at 1-month pretransplantation, despite the fact that blood was drawn at any time between 1 month pretransplantation and the morning of starting conditioning. Day 0 studies were performed using blood drawn immediately before graft infusion. Nine patient blood samples were analyzed before transplantation, 7 were analyzed on day 0, 6 were analyzed at 1 month posttransplantation, 8 were analyzed at 3 months posttransplantation, 6 were analyzed at 6 months posttransplantation, and 5 were analyzed at 12 months posttransplantation. Biology of Blood and Marrow Transplantation 2010 16, 384-394DOI: (10.1016/j.bbmt.2009.11.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Recovery of lymphocyte subsets. Recovery of NK, B cells, dendritic cell precursors, CD4+ and CD8+ T cells after transplantation (A). Recovery of naive, memory/effector, CD28+ or CD28−, CD4+ and CD8+ T cells after transplantation (B). The y-axis shows the number of cells per microliter of blood. Patient medians (diamonds) and 25th-75th percentiles (error bars) are displayed. Normal medians (of 104 normal adults) are indicated by the dashed horizontal lines; the thick horizontal lines denote the normal 10th-90th percentiles. Pretransplantation studies are arbitrarily shown as performed using blood collected at 1-month pretransplantation, despite the fact that blood was drawn at any time between 1 month pretransplantation and the morning of starting conditioning. Day 0 studies were performed using blood drawn immediately before graft infusion. Nine patient blood samples were analyzed before transplantation, 7 were analyzed on day 0, 6 were analyzed at 1 month posttransplantation, 8 were analyzed at 3 months posttransplantation, 6 were analyzed at 6 months posttransplantation, and 5 were analyzed at 12 months posttransplantation. Biology of Blood and Marrow Transplantation 2010 16, 384-394DOI: (10.1016/j.bbmt.2009.11.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions